Biological E receives DCGI approval for administration of Corbevax in children aged 12 to 18 years
Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) Protein subunit vaccine against COVID-19. The vaccine had already received approval for restricted use in emergency situations among adults.
Biological E. Limited (BE) today received Emergency Use Authorisation (EUA) from the Drugs Controller General of India (DCGI) for the administration of its Corbevax vaccine in children aged 12 to 18 years. The approval for restricted use in an emergency situation by the Indian drug regulator was granted on the basis of interim results of the ongoing phase II/III clinical study. Corbevax is India's first indigenously developed Receptor Binding Domain (RBD) Protein subunit vaccine against COVID-19. The vaccine had already received approval for restricted use in emergency situations among adults on December 28, 2020. Highlighting the benefits of expanding the vaccine to children, Mahima Datla, Managing Director, Biological E. Limited, said,
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!